Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | NPC1 | O15118 | 2/20 | 0.60 |
| ▸ | RAB9A | P51151 | 2/20 | 0.60 |
| ▸ | GMNN | O75496 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | HTR1A | P08908 | 1/20 | 0.60 |
| ▸ | THRB | P10828 | 1/20 | 0.60 |
| ▸ | PIM1 | P11309 | 1/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | MAOA | P21397 | 1/20 | 0.60 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.60 |
| ▸ | HTR2A | P28223 | 1/20 | 0.60 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.60 |
| ▸ | CCKBR | P32239 | 1/20 | 0.60 |
| ▸ | MC4R | P32245 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | THPO | P40225 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1827469 | 0.85 | NPC1 (0.46) | SMN1; SMN2NPC1RAB9AGMNNLMNA | |
| SCHEMBL6707284 | 0.82 | FLT1 (0.51) | SMN1; SMN2NPC1RAB9AGMNNLMNA | |
| SCHEMBL6709304 | 0.82 | KIF11 (0.48) | SMN1; SMN2NPC1RAB9AGMNNLMNA | |
| SCHEMBL8464779 | 0.80 | LSS (0.51) | SMN1; SMN2EPHX2P2RX7 | |
| SCHEMBL22556400 | 0.80 | RXFP1 (0.46) | SMN1; SMN2RAB9AHTTPTGS1 | |
| SCHEMBL6709286 | 0.79 | SMN1; SMN2 (0.49) | SMN1; SMN2NPC1RAB9AGMNNLMNA | |
| SCHEMBL24049743 | 0.79 | DHODH (0.60) | SMN1; SMN2NPC1RAB9AGMNNLMNA | |
| SCHEMBL16363170 | 0.79 | TRPV1 (0.44) | SMN1; SMN2NPC1RAB9AGMNNLMNA | |
| SCHEMBL6707208 | 0.77 | SMN1; SMN2 (0.47) | SMN1; SMN2NPC1RAB9AGMNNLMNA | |
| SCHEMBL6707863 | 0.77 | NPC1 (0.47) | SMN1; SMN2NPC1RAB9AGMNNLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160326590-A1 | TH17 DIFFERENTIATION MARKERS FOR ACNE AND USES THEREOF | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2016-11-10 | — | — | US | claimed |
| US-20140235475-A1 | TH17 DIFFERENTIATION MARKERS FOR ACNE AND USES THEREOF | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2014-08-21 | — | — | US | claimed |
| US-20140221648-A1 | TH17 DIFFERENTIATION MARKERS FOR ACNE AND USES THEREOF | GALDERMA RESEARCH & DEVELOPEMENT (FR) | 2014-08-07 | — | — | US | claimed |
| US-20140221231-A1 | TH-17 DIFFERENTIATION MARKERS FOR ROSACEA AND USES THEREOF | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2014-08-07 | — | — | US | claimed |
| EP-2723893-A1 | NEW TH-17 DIFFERENTIATION MARKERS FOR ROSACEA AND USES THEREOF | Galderma Research & Development (FR) | 2014-04-30 | — | — | EP | claimed |
| EP-2723889-A1 | NEW TH17 DIFFERENTIATION MARKERS FOR ACNE AND USES THEREOF | Galderma Research & Development (FR) | 2014-04-30 | — | — | EP | claimed |
| EP-2723890-A1 | NEW TH17 DIFFERENTIATION MARKERS FOR ACNE AND USES THEREOF | Galderma Research & Development (FR) | 2014-04-30 | — | — | EP | claimed |
| WO-2013000869-A1 | NEW TH17 DIFFERENTIATION MARKERS FOR ACNE AND USES THEREOF | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2013-01-03 | — | — | WO | claimed |
| WO-2013000871-A1 | NEW TH-17 DIFFERENTIATION MARKERS FOR ROSACEA AND USES THEREOF | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2013-01-03 | — | — | WO | claimed |
| WO-2013000870-A1 | NEW TH17 DIFFERENTIATION MARKERS FOR ACNE AND USES THEREOF | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2013-01-03 | — | — | WO | claimed |
| US-20040127532-A1 | Method for synthesizing leflunomide | AVRUTOV ILYA (IL) | 2004-07-01 | — | — | US | claimed |
| US-6723855-B2 | CHLORINATING 5-METHYLISOXAZOLE-4-CARBOXYLIC ACID BY REACTING WITH CHLORINATING AGENT TO FORM 5-METHYLISOXAZOLE-4-CARBOXYLIC ACID CHLORIDE, REACTING WITH 4-TRIFLUOROMETHYLANILINE IN PRESENCE OF ALKALI METAL OR ALKALINE EARTH METAL BICARBONATE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2004-04-20 | — | — | US | claimed |
| JP-2004500380-A | — | — | 2004-01-08 | — | — | JP | claimed |
| EP-1257270-A4 | A METHOD FOR SYNTHESIZING LEFLUNOMIDE | TEVA PHARMA (IL) | 2003-05-07 | — | — | EP | claimed |
| EP-1257270-A1 | A METHOD FOR SYNTHESIZING LEFLUNOMIDE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2002-11-20 | — | — | EP | claimed |
| US-20020022646-A1 | Method for systhesizing leflunomide | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2002-02-21 | — | — | US | claimed |
| WO-2001060363-A1 | A METHOD FOR SYNTHESIZING LEFLUNOMIDE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2001-08-23 | — | — | WO | claimed |
| CN-110669022-B | Micro-channel continuous preparation method of 5-methyl isoxazole-4-formic acid | 常州沃腾化工科技有限公司 | 2022-03-11 | — | — | CN | disclosed |
| WO-1999045908-A2 | ANTI-VIRAL USES OF LEFLUNOMIDE PRODUCTS | OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 1999-09-16 | — | — | WO | disclosed |
| WO-1998052944-A1 | HETEROARYLCARBOXAMIDE COMPOUNDS ACTIVE AGAINST PROTEIN TYROSINE KINASE RELATED DISORDERS | SUGEN, INC. (US) | 1998-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020022646-A1 | Method for systhesizing leflunomide | FAH, LEF1, HMGCR | SMN1; SMN2 570/4885NPC1 1244/4885RAB9A 2074/4885 |
| US-20040127532-A1 | Method for synthesizing leflunomide | LEF1, CYP3A5, CYP2F1 | SMN1; SMN2 1333/4885NPC1 956/4885RAB9A 2319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.